Ligand Pharmaceuticals (LGND) Non-Current Deferred Tax Liability (2010 - 2026)

Ligand Pharmaceuticals has reported Non-Current Deferred Tax Liability for 14 years, with the latest figure at $22.6 million in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 23.03% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.6 million (down 23.03% YoY) and the FY2025 annual result came in at $36.0 million, down 50.75% from the prior year.
• Non-Current Deferred Tax Liability declined to $22.6 million in Q1 2026 per LGND's latest filing, from $36.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $73.1 million in Q4 2024 and troughed at $22.6 million in Q1 2026.
• A 5-year average of $35.7 million and a median of $31.6 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deferred Tax Liability tumbled 57.66% in 2022, then soared 131.3% in 2024.
• Over 5 years, Non-Current Deferred Tax Liability stood at $30.6 million in 2022, then gained by 3.29% to $31.6 million in 2023, then jumped by 131.3% to $73.1 million in 2024, then tumbled by 50.75% to $36.0 million in 2025, then plunged by 37.22% to $22.6 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $22.6 million, $36.0 million, and $22.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.